Latest Asx News

TruScreen Group Limited forecasts a robust 64% increase in FY26 sales, driven by strategic market expansions and new distribution agreements. The company’s AI-enabled cervical cancer screening technology is gaining traction across emerging markets.

QEM Limited's trading suspension has been lifted immediately following its announcement of a new capital raise, signaling a pivotal moment for the company’s financial strategy.

Gold Mountain Limited has issued nearly 486 million shortfall shares to underwriter Jose Luis Manzano, lifting its recent trading halt. A second tranche to Magnus Capital awaits shareholder approval, marking a pivotal step in the company’s capital raising.

Knosys Limited is reshaping its future by focusing on its Libero library management platform, aiming to become a global leader through strategic simplification, AI innovation, and geographic expansion.

ReadCloud Limited reports a robust first half FY25 with 13% organic revenue growth and a 73% jump in underlying EBITDA, powered by its expanding VET-in-Schools segment and disciplined cost management.

The ACCC has issued a preliminary Statement of Issues regarding Elders Limited’s proposed acquisition of Delta Agribusiness, signaling potential competition challenges that could affect the deal’s timeline.

Ionic Rare Earths has announced a $3 million capital raise via convertible notes, aimed at advancing its rare earth projects across multiple continents. The raise, pending shareholder approval, underscores the company’s strategic push into sustainable rare earth extraction and recycling technologies.

Elsight Limited has expanded its supply agreement with a European defence drone OEM to a total of US$9.63 million for 2025, positioning the company for profitability and cash flow break-even this year.

Uvre has cleared a crucial regulatory hurdle in its acquisition of New Zealand’s Waitekauri Gold Project, setting the stage for new leadership and exploration activities.

Javelin Minerals’ maiden drilling at the Eureka Gold Project reveals significant high-grade gold mineralisation outside the existing resource, setting the stage for near-term mining and resource expansion.

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.

Agrimin Limited has successfully raised $2.5 million through an oversubscribed equity placement to fund the strategic review of its Mackay Potash Project and explore new mineral opportunities.